Abstract: Provided are a catalyst for olefin polymerization including a hybrid catalyst composition and an olefin-based polymer prepared therefrom. The hybrid metallocene catalyst allows preparation of an olefin polymer having a broad molecular weight distribution and excellent high-speed processability. In addition, an olefin-based polymer prepared in the presence of the hybrid catalyst has a broad molecular weight distribution and excellent high-speed processability.

Abstract: Provided are a method for preparing an olefin-based polymer and an olefin-based polymer produced using the same. The method for preparing an olefin-based polymer according to an exemplary embodiment may adjust processability of the olefin-based polymer produced using the method by a polymerization temperature. In addition, the method for preparing an olefin-based polymer according to the exemplary embodiment may adjust drop impact strength of a finally obtained film by a polymerization temperature.

Abstract: A display device includes a display area including a first light-emitting area and a second light-emitting area; a peripheral area adjacent to the display area; pixels which emit incident light; an encapsulation layer covering the pixels; a first color-converting pattern corresponding to the first light-emitting area and having a refractivity; a transmission pattern corresponding to the second light-emitting area and through which the incident light is transmitted; a low refractivity layer is in the display area and facing the encapsulation layer with each of the first color-converting pattern and the transmission pattern therebetween, the low refractivity layer including: a resin and a hollow particle which define a refractivity lower than the refractivity of the first color-converting pattern; and a first dam structure in the peripheral area and spaced apart from the display area, the first dam structure and the transmission pattern being portions of a same material layer.

Abstract: The present invention relates to a novel chimeric antigen receptor comprising a CD99L2 region, which is known to play a key role in cell adhesion and migration, as a backbone of the chimeric antigen receptor, an immune cell comprising the same, and the uses thereof. CD99L2-based CAR-T cells exhibit enhanced T-cell activity and tumor treatment efficiency compared to conventional CAR-T cells, and thus can be useful in immune cell therapy for the treatment of cancer.

Abstract: The present invention relates to a pharmaceutical composition for treating and/or preventing arthritis, which comprising, as an active ingredient, a gene delivery vehicle into which an IK factor or a fragment thereof, or a nucleic acid encoding thereof is inserted. IK factor or the fragment thereof, and the nucleic acid encoding thereof, which are the active ingredient of the pharmaceutical composition according to the present invention, are derived from an organism and therefore, show no side effects in administered into a subject for a long time. Accordingly, they ensures safety and are expected to effectively treat arthritis by being involved in the upstream mechanism for suppressing arthritis.

Abstract: The present invention relates to a pharmaceutical composition for treating and/or preventing arthritis, which comprising, as an active ingredient, a gene delivery vehicle into which an IK factor or a fragment thereof, or a nucleic acid encoding thereof is inserted. IK factor or the fragment thereof, and the nucleic acid encoding thereof, which are the active ingredient of the pharmaceutical composition according to the present invention, are derived from an organism and therefore, show no side effects in administered into a subject for a long time. Accordingly, they ensures safety and are expected to effectively treat arthritis by being involved in the upstream mechanism for suppressing arthritis.

Abstract: The present invention relates to a pharmaceutical composition for treating and/or preventing arthritis, which comprising, as an active ingredient, a gene delivery vehicle into which an IK factor or a fragment thereof, or a nucleic acid encoding thereof is inserted. IK factor or the fragment thereof, and the nucleic acid encoding thereof, which are the active ingredient of the pharmaceutical composition according to the present invention, are derived from an organism and therefore, show no side effects in administered into a subject for a long time. Accordingly, they ensures safety and are expected to effectively treat arthritis by being involved in the upstream mechanism for suppressing arthritis.

Abstract: The present invention relates to a pharmaceutical composition for treating and/or preventing arthritis, which comprising, as an active ingredient, a gene delivery vehicle into which an IK factor or a fragment thereof, or a nucleic acid encoding thereof is inserted. IK factor or the fragment thereof, and the nucleic acid encoding thereof, which are the active ingredient of the pharmaceutical composition according to the present invention, are derived from an organism and therefore, show no side effects in administered into a subject for a long time. Accordingly, they ensures safety and are expected to effectively treat arthritis by being involved in the upstream mechanism for suppressing arthritis.